Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?

Group 1 - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market over the next 30 days, based on value, growth, and momentum characteristics [2][3] Group 2 - Each stock is rated from A to F, with A indicating the highest potential for outperformance, and the Style Scores are categorized into Value, Growth, Momentum, and a combined VGM Score [3][4][6] - The Value Score focuses on identifying undervalued stocks using financial ratios, while the Growth Score assesses a company's financial health and future growth potential [3][4] - The Momentum Score identifies trends in stock prices and earnings estimates, helping investors time their positions effectively [5] Group 3 - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.64% since 1988, significantly outperforming the S&P 500 [7][9] - Investors are encouraged to consider stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal return potential [9][10] Group 4 - Catalyst Pharmaceuticals, Inc. is highlighted as a stock to watch, currently holding a 3 (Hold) Zacks Rank and a VGM Score of A, with a forward P/E ratio of 8.74 indicating attractive valuation [11] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate for fiscal 2025 increasing by $0.04 to $2.29 per share, and an average earnings surprise of +24.1% [12]